Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Travatan without BAK in adults with open-angle glaucoma or ocular hypertension previously on latanoprost or bimatoprost monotherapy
2011-003816-21Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Change in intraocular pressure at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2011-003816-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003816-21.